PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Protagonist Therapeutics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$134.44+5.69 (+4.42%)
Close on Oct 19, 2026
- Market cap
- $9.55B
- P/E (TTM)
- 130.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Operating margin
-343.6%−118.3 pts over 5 years
Net margin
-282.8%−51.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -89.4% | +20.1% | +10.0% | – | |
| Free cash flow | -69.3% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -123.6% | -36.8% | -20.2% | |
| Return on assets | -68.3% | -27.6% | -18.4% | |
| Current ratio | 12.94 | 7.84 | 12.71 | |
| Interest coverage | – | -107.9× | – | |
| Capex to revenue | – | 1.6% | 3.5% | |
| Diluted shares | 7M | 34M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Protagonist Therapeutics generated $528.06M from operations and spent $5.45M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$528.06M
Used
$5.45M
Capital expenditure$5.45M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-282.8%
×Asset turnover0.07×
×Equity multiplier1.10×
=Return on equity, FY2025-20.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -282.8% | 0.07× | 1.10× | -20.2% |
| FY2024 | 63.3% | 0.79× | 1.09× | 54.4% |
| FY2023 | -131.6% | 0.20× | 1.10× | -28.6% |
| FY2022 | -479.3% | 0.09× | 1.16× | -49.4% |
| FY2021 | -458.9% | 0.08× | 1.16× | -43.3% |
| FY2020 | -231.1% | 0.12× | 1.33× | -36.8% |
| FY2019 | -33414.3% | 0.00× | 1.53× | -80.2% |
| FY2018 | -125.9% | 0.20× | 1.30× | -33.4% |
| FY2017 | -184.2% | 0.16× | 1.24× | -35.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$130.15M
- Cash generatingOperating cash flow above zero$57.67M
- Return on assets improvedROA up on the prior year76.9% → -17.5%
- Earnings backed by cashOperating cash flow above net income$57.67M vs -$130.15M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose12.48 → 12.71
- No dilutionShare count did not rise65M → 64M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.21 → 0.06